Since the disclosure of cancer-causing genetic biomarkers, many of these biomarkers like BRCA1/BRCA2, EGFR, and BRAF, have been fused into the standard of care treatment. Quick genomic screening is currently possible with the help of new technologies that are available in the process of new sequencing. The Cancer Genome Atlas and International Cancer Genome Consortium have examined the enormous of malignant growth partners. This has revealed new biomarker classes to enhance the control of and promise safe treatment. In a period of emotional extension of sequencing ability, ctDNA examination is one of the most encouraging methods for fast clinical interpretation by empowering non-intrusive, delicate, and explicit hereditary testing and checking. Also, encouraging novel biomarkers recognized in mass tissue can be converted into ctDNA sequencing or methylomic markers to reveal transient advancement.
Then, progressing headway in the ctDNA examination is important to defeat noteworthy difficulties. Expanded affectability and diminished inclusion inclination are fundamental for the examination of TMB and change marks. This will require further investigation into a research facility.
REf art: https://www.clinicaloncologyonline.net/article/S0936-6555(20)30234-X/fulltext
